Travere Therapeutics (TVTX) to Release Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) will be announcing its earnings results after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million during the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The firm’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) EPS. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Trading Down 3.2 %

Shares of NASDAQ TVTX traded down $0.33 during midday trading on Tuesday, reaching $9.86. The stock had a trading volume of 195,688 shares, compared to its average volume of 1,220,574. The firm has a market cap of $750.63 million, a price-to-earnings ratio of -4.85 and a beta of 0.77. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $17.57. The company has a debt-to-equity ratio of 5.10, a quick ratio of 2.75 and a current ratio of 2.78. The company’s 50 day moving average price is $8.12 and its 200 day moving average price is $7.74.

Wall Street Analysts Forecast Growth

TVTX has been the topic of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Canaccord Genuity Group lifted their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, May 7th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.64.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.